Pembrolizumab for Heavily Pretreated Patients With Advanced Carcinoma of the Esophagus

This phase 2, open-label, interventional study examined the safety and efficacy of pembrolizumab for patients with advanced, metastatic esophageal carcinoma that has progressed after 2 or more lines of systemic therapy.

https://ift.tt/2ScIHM9